A 48-year-old woman was treated with toripalimab for triple negative breast cancer. She developed symptoms of pollakiuria and urinary urgency after 1st cycle of toripalimab, and was hospitalized for severe abdominal pain after 2nd circle of treatment, after symptomatic treatment, the condition improved. However, after the 3rd, 4th, and 5th cycles of medication, the symptoms recurred. The symptoms did not reappear after discontinuing toripalimab. Therefore, ureteritis associated with immune checkpoint inhibitors (ICI) was considered based on case characteristics, urine routine, urine culture, ultrasound and CT findings. According to Naranjo's Assessment Scale, the association between toripalimab and ureteritis was considered “definite”. The possibility of ureteritis associated with ICI should be considered if symptoms of urinary tract irritation occur during the use of toripalimab, and urine analysis, urine culture, and imaging examination should be conducted to detect such adverse reactions earlier.

1.杨丹, 王金秀, 毛大华. 免疫治疗及抗体偶联药物治疗三阴性乳腺癌的临床研究进展[J]. 中国药师, 2024, 27(5): 901-908. [Yang D, Wang JX, Mao DH. Progress of clinical research on immunotherapy and antibody-drug conjugates for the treatment of triple-negative breast cancer[J]. China Pharmacist, 2024, 27(5): 901-908.] DOI: 10.12173/j.issn.1008-049X.202402077.

2.Jiang Z, Ouyang Q, Sun T, et al. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial[J]. Nat Med, 2024, 30(1): 249-256. DOI: 10.1038/s41591-023-02677-x.

3.Li L, Li G, Rao B, et al. Landscape of immune checkpoint inhibitor-related adverse events in Chinese population[J]. Sci Rep, 2020, 10(1): 15567. DOI: 10.1038/s41598-020-72649-5.

4.Fan Y, Zhao J, Mi Y, et al. Recurrent cystitis associated with 2 programmed death 1 inhibitors: a rare case report and literature review[J]. J Immunother, 2023, 46(9): 341-345. DOI: 10.1097/CJI.0000000000000484.

5.李师师, 郑可, 徐燕, 等. 免疫检查点抑制剂相关输尿管膀胱炎: 病例报道1例及文献复习[J]. 中国肺癌杂志, 2023, 26(9): 709-716. [Li SS, Zheng K, Xu Y, et al. Immune checkpoint inhibitors related cystoureteritis: a case report and literature review[J]. Chinese Journal of Lung Cancer, 2023, 26(9): 709-716]. DOI: 10.3779/j.issn.1009-3419.2023.106.17.

6.Zhou Q, Qin Z, Yan P, et al. Immune-related adverse events with severe pain and ureteral expansion as the main manifestations: a case report of tislelizumab-induced ureteritis/cystitis and review of the literature[J]. Front Immunol, 2023, 14: 1226993. DOI: 10.3389/fimmu.2023.1226993.

7.Ni CX, Zhao Y, Qian H, et al. Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: a case report[J]. Front Pharmacol, 2023, 14: 1121122. DOI: 10.3389/fphar.2023.1121122.

8.张顺, 丁秋播, 庄君龙. 膀胱癌新辅助免疫治疗引起免疫相关性膀胱炎二例[J]. 临床外科杂志, 2022, 30(3): 276-279. [Zhang S, Ding QB, Zhuang JL. 2 cases of immune-related cystitis caused by neoadjuvant immunotherpy for bladder cancer[J].Journal of Clinical Surgery, 2022, 30(3): 276-279]. DOI: 10.3969/j.issn.1005-6483.2022.03.021.

9.Yajima S, Nakanishi Y, Matsumoto S, et al. Improvement of urinary symptoms after bladder biopsy: a case of pathologically proven allergy-related cystitis during administration of nivolumab[J]. IJU Case Rep, 2021, 4(4): 213-215. DOI: 10.1002/iju5.12286.

10.Zhu S, Bian L, Lyu J, et al. A case report of non-bacterial cystitis caused by immune checkpoint inhibitors[J]. Front Immunol, 2021, 12: 788629. DOI: 10.3389/fimmu.2021.788629.

11.Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245. DOI: 10.1038/clpt.1981.154.

12.Fukunaga H, Sumii K, Kawamura S, et al. A case of steroid-resistant cystitis as an immune-related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab[J]. IJU Case Rep, 2022, 5(6): 521-523. DOI: 10.1002/iju5.12532.

13.Obayashi A, Hamada-Nishimoto M, Fujimoto Y, et al. Non-bacterial cystitis with increased expression of programmed cell death ligand 1 in the urothelium: an unusual immune-related adverse event after atezolizumab administration for metastatic breast cancer[J]. Cureus, 2022, 14(5): e25486. DOI: 10.7759/cureus.25486.

14.Zhu L, Wang Z, Stebbing J, et al. Immunotherapy-related cystitis: case report and review of the literature[J]. Onco Targets Ther, 2021, 14: 4321-4328. DOI: 10.2147/OTT.S321965.

15.He X, Tu R, Zeng S, et al. Non-bacterial cystitis secondary to pembrolizumab: a case report and review of the literature[J]. Curr Probl Cancer, 2022, 46(4): 100863. DOI: 10.1016/j.currproblcancer.2022.100863.

16.张志龙, 山长婷, 徐静, 等. 信迪利单抗和贝伐珠单抗联合治疗肺腺癌致免疫性输尿管炎/膀胱炎1例报告及文献复习 [J].中国肿瘤生物治疗杂志, 2023, 30(6): 533-537. [Zhang ZL, Shan CT, Xu J, et al. Immune-related ureteritis/cystitis caused by lung adenocarcinoma treated with combination of sintilimab and bevacizumab: a case report and literature review[J]. Chinese Journal of Cancer Biotherapy, 2023, 30(6): 533-537]. DOI: 10.3872/j.issn.1007-385x.2023.06.012.

17.秦叔逵, 王宝成, 郭军等, 主编. 中国临床肿瘤学会（CSCO）免疫检查点抑制剂相关的毒性管理指南[M]. 北京: 人民卫生出版社, 2023: 146-149.

18.Shimatani K, Yoshimoto T, Doi Y, et al. Two cases of nonbacterial cystitis associated with nivolumab, the anti-programmed-death-receptor-1 inhibitor[J]. Urol Case Rep, 2018, 17: 97-99. DOI:  10.1016/j.eucr.2017.12.006.

19.Tu L, Ye Y, Tang X, et al. Case report: a case of sintilimab-induced cystitis/ureteritis and review of sintilimab-related adverse events[J]. Front Oncol, 2021, 11: 757069. DOI: 10.3389/fonc.2021.757069.

20.Wang Z, Zhu L, Huang Y, et al. Successful treatment of immune-related cystitis by Chai-Ling-Tang (Sairei-To) in a gastric carcinoma patient: case report and literature review[J]. Explore (NY), 2023, 19(3): 458-462. DOI: 10.1016/j.explore.2022.04.002.

21.Anraku T, Hashidate H, Imai T, et al. Successful treatment of immune-related cystitis with bladder hydrodistension[J]. IJU Case Rep, 2023, 6(4): 211-215. DOI: 10.1002/iju5.12588.

22.Schneider S, Alezra E, Yacoub M, et al. Aseptic cystitis induced by nivolumab and ipilimumab combination for metastatic melanoma[J]. Melanoma Res, 2021, 31(5): 487-489. DOI: 10.1097/CMR.0000000000000765.

23.Li J, Yu YF, Qi XW, et al. Immune-related ureteritis and cystitis induced by immune checkpoint inhibitors: case report and literature review[J]. Front Immunol, 2023, 13: 1051577. DOI: 10.3389/fimmu.2022.1051577.

24.徐媛玉. 中西医结合治疗泌尿外科患者常见尿路感染情况的Meta分析及相关临床研究[D]. 武汉: 湖北中医药大学, 2023. DOI: 10.27134/d.cnki.ghbzc.2022.000066.

25.袁帅, 梁艳, 衡琪琪, 等. 缩泉丸作用机制研究及现代临床应用进展[J]. 山西中医, 2023, 39(5): 58-60. [Yuan S, Liang Y, Heng QQ, et al. Research progress on modern clinical application and mechanism of Suoquan Wan[J]. Shanxi Journal of TCM, 2023, 39(5): 58-60.] DOI: 10.20002/j.issn.1000-7156.2023.05.024.